AIRC Regorafenib in glioblastoma: molecular characterization of tumor response and translational opportunities (DSB.AD001.225)

Area tematica

Scienze biomediche

Area progettuale

Struttura responsabile del progetto di ricerca

Istituto di Biochimica e Biologia Cellulare (IBBC)

Responsabile di progetto

MARIALAURA FALCHETTI
Telefono: 0690091
E-mail: marialaura.falchetti@cnr.it

Abstract

Glioblastoma (GBM) is the most malignant brain tumor in adults, with median survival of 14.6 months (Stupp, 2009). It has a relevant social impact because the peak incidence coincides with the age of professional maturity. GBM prognosis did not significantly improve in the last fifteen years. Recently, the multikinase inhibitor regorafenib demonstrated a significant increase of overall survival (OS) in the phase II trial REGOMA on patients with relapsed GBM (Lombardi, 2019). This is the first drug since the introduction of temozolomide,to demonstrate efficacy in GBM prognosis. On this basis, National Comprehensive Cancer Network (NCCN) 2020 Guidelines included regorafenib as a preferred regimen in relapsed GBM treatment, and the Italian Agency of Medicine (AIFA) approved regorafenib for Italian recurrent GBM patients. Despite the use in GBM patients' therapy, little is known about the molecular mechanisms governing regorafenib effectiveness on tumor.
Hypothesis
Our hypothesis is that the outcome of regorafenib in GBM treatment might be strongly improved through the
identification of regulators driving GBM responsiveness to regorafenib.
Aims
The project focuses on three main goals:

Data inizio attività

01/01/2022

Parole chiave

Glioma and/or glioblastoma, Drug response and/or resistance, Cancer stem cells

Ultimo aggiornamento: 02/01/2025